New combo therapy aims to Fast-Track UC remission
NCT ID NCT06095596
First seen May 03, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This study tests a sequential treatment for moderate to severe ulcerative colitis. Patients first receive a fast-acting drug (upadacitinib) for 8 weeks, then switch to a safer long-term drug (vedolizumab) for maintenance. The goal is to quickly induce remission while reducing side effects. About 334 participants will be enrolled across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the Sixth Affiliated Hospital of Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 501655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vedolizumab and upadacitinib
What this could lead to
If successful, this could offer a new treatment sequence that quickly controls ulcerative colitis symptoms and maintains remission with a good safety profile.
What could go wrong
This is an early-stage study with no phase designation, so results are uncertain. The combination may not improve outcomes over standard treatments, and upadacitinib carries risks like infection and blood clots.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.